Tokyo: Ranbaxy Laboratories Ltd may shift some generic drug production from India to the US in response to an import ban by the US authorities, chief executive officer Malvinder Singh said.
Another option for Ranbaxy is to buy factories approved by the US Food and Drug Administration (FDA), Singh said in Tokyo on Thursday. The FDA on 16 September blocked imports of medicines made in two Indian factories of Ranbaxy because it had doubts over quality control. The regulator said there was no evidence that Ranbaxy’s drugs were harmful.
Step ahead: A file photo of Ranbaxy’s Malvinder Singh. The US FDA had questioned the company’s quality control specifications. Harikrishna Katragadda / Mint
The FDA probed whether Gurgaon-based Ranbaxy destroyed reports it was required to keep, falsified data and failed to meet quality control specifications in manufacturing the generic drugs it sells.
The Indian company has denied the allegations and agreed to produce all the documents.
Ranbaxy was purchased by Daiichi Sankyo Co., Japan’s third largest drug maker, last year.
Separately, Nippon Chemiphar Co., a Japanese drug maker, said it was in talks with Ranbaxy about possibly ending a venture that produces generic drugs in Japan.
Nothing about the ties has been decided, Nippon Chemiphar spokesman Kunio Oka said over the telephone on Thursday. Nippon Chemiphar and Ranbaxy now hold 50% each in the venture formed in 2002.
Ranbaxy plans to sell its half to Nippon Chemiphar, the ‘Nikkei English News’ reported earlier.